-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ascend Pharmaceuticals (6855.
HK), a clinical research and development company dedicated to the development of innovative drugs in the treatment of tumors, hepatitis B and aging-related diseases, announced that it will be based on the latest semi-annual review results published by the world's leading index company MSCI , The company is included in the MSCI China Small Index constituent stocks, and the relevant adjustments will take effect after the market closes on May 27, 2021 (Thursday)
.
The MSCI China Small Cap Index is compiled by MSCI to measure the performance of the small cap sector in the Chinese market, covering companies with good business performance and development potential
.
The index is widely adopted and referenced by professional investment professionals around the world
After being included in the Hang Seng Composite Index and other three major indexes and the Southbound Stock Connect last year, Yasheng Pharmaceutical has become a constituent stock of the MSCI China Small Cap Index this time, fully demonstrating the R&D strength, development strategy and investment value of Yasheng Pharmaceutical in the international capital market.
And recognition of future prospects
.
As the first stock of original small molecule new drugs in the Hong Kong stock market, since its listing in October 2019, Yasheng Pharmaceuticals has made great progress in clinical development, foreign cooperation, patent layout, etc.
, and has reached a number of global cooperations.
From the original innovative drug R&D company to the new drug R&D and manufacturing company
.
The company successfully submitted its first new drug listing application (NDA) last year and was included in the priority review, setting a major milestone
Dr.
Yang Dajun, Chairman and CEO of Yasheng Pharmaceuticals, said: "The inclusion of the MSCI China Small Index component stocks fully reflects the capital market’s recognition and confidence in the company’s business and development prospects, and will help the company introduce more diversified investments To enhance the liquidity of stocks and further increase the company’s reputation in the international capital market
.
In the future, Yasheng Pharmaceuticals will continue to use its R&D advantages, accelerate the global clinical development of existing product pipelines, promote the process of new drug listing applications, and benefit patients around the world as soon as possible.
